The US Leads The World In The Weight-Loss Injection Boom

The US Leads The World In The Weight-Loss Injection Boom Novo Nordisk’s obesity-drug franchise has surged at a remarkable pace. In just four years, revenue from its weight-management treatments ballooned roughly tenfold - from about $1.3 billion in 2021 to approximately $12.4 billion in 2025. The growth has been fueled largely by Wegovy, the company’s blockbuster weight-loss drug built around the active ingredient semaglutide and marketed as a once-weekly injection. Semaglutide ...

By Tyler Durden